Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2016 2
2019 1
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
Kennedy EM, Denslow A, Hewett J, Kong L, De Almeida A, Bryant JD, Lee JS, Jacques J, Feau S, Hayes M, McMichael EL, Wambua D, Farkaly T, Rahmeh AA, Herschelman L, Douglas D, Spinale J, Adhikari S, Deterling J, Scott M, Haines BB, Finer MH, Ashburn TT, Quéva C, Lerner L. Kennedy EM, et al. Among authors: wambua d. Nat Commun. 2022 Oct 7;13(1):5907. doi: 10.1038/s41467-022-33599-w. Nat Commun. 2022. PMID: 36207308 Free PMC article.
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J, Wambua D, Kong L, Behera P, Jacques J, Goshert C, Ball M, Colthart A, Finer MH, Hayes MW, Feau S, Kennedy EM, Lerner L, Quéva C. Haines BB, et al. Among authors: wambua d. Cancer Immunol Res. 2021 Mar;9(3):291-308. doi: 10.1158/2326-6066.CIR-20-0609. Epub 2020 Dec 22. Cancer Immunol Res. 2021. PMID: 33355229
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.
Kennedy EM, Farkaly T, Grzesik P, Lee J, Denslow A, Hewett J, Bryant J, Behara P, Goshert C, Wambua D, De Almeida A, Jacques J, Deavall D, Rottman JB, Glorioso JC, Finer MH, Haines BB, Quéva C, Lerner L. Kennedy EM, et al. Among authors: wambua d. Mol Ther Oncolytics. 2020 Aug 8;18:476-490. doi: 10.1016/j.omto.2020.08.004. eCollection 2020 Sep 25. Mol Ther Oncolytics. 2020. PMID: 32953982 Free PMC article.